A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED, LOT-TO-LOT CONSISTENCY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN ADULTS 18 TO 49 YEARS OF AGE

Registry ID

V116-004

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2022-09-08

Last update

2022-07-28

Conditions

• PNEUMONIA

Related clinical trials

• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUNCTIVE RECOMBINANT HUMAN PLASMA GELSOLIN WITH STANDARD OF CARE FOR MODERATE-TO-SEVERE ARDS DUE TO PNEUMONIA OR OTHER INFECTIONS
• SHORT-COURSE ANTIMICROBIAL THERAPY FOR PAEDIATRIC RESPIRATORY INFECTION (SAFER): A MULTICENTRE, RANDOMIZED, CONTROLLED, NON-INFERIORITY TRIAL

View on source registry